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Abstract
Introduction: The optimal blood glucose target following severe traumatic brain injury (TBI) must be defined. Cerebral 
microdialysis was used to investigate the influence of arterial blood and brain glucose on cerebral glucose, lactate, 
pyruvate, glutamate, and calculated indices of downstream metabolism.
Methods: In twenty TBI patients, microdialysis catheters inserted in the edematous frontal lobe were dialyzed at 1 μl/
min, collecting samples at 60 minute intervals. Occult metabolic alterations were determined by calculating the 
lactate- pyruvate (L/P), lactate- glucose (L/Glc), and lactate- glutamate (L/Glu) ratios.
Results: Brain glucose was influenced by arterial blood glucose. Elevated L/P and L/Glc were significantly reduced at 
brain glucose above 1 mM, reaching lowest values at blood and brain glucose levels between 6-9 mM (P < 0.001). 
Lowest cerebral glutamate was measured at brain glucose 3-5 mM with a significant increase at brain glucose below 3 
mM and above 6 mM. While L/Glu was significantly increased at low brain glucose levels, it was significantly decreased 
at brain glucose above 5 mM (P < 0.001). Insulin administration increased brain glutamate at low brain glucose, but 
prevented increase in L/Glu.
Conclusions: Arterial blood glucose levels appear to be optimal at 6-9 mM. While low brain glucose levels below 1 mM 
are detrimental, elevated brain glucose are to be targeted despite increased brain glutamate at brain glucose >5 mM. 
Pathogenity of elevated glutamate appears to be relativized by L/Glu and suggests to exclude insulin- induced brain 
injury.
Introduction
Hyperglycemia aggravates underlying brain damage and
influences both morbidity and mortality in critically ill
patients [1-3] by inducing tissue acidosis [1,2], oxidative
stress, and cellular immunosuppression [4] which, in turn,
promote the development of multiorgan failure [5]. Hypo-
glycemia impairs energy supply causing metabolic pertur-
bation [6] and inducing cortical spreading depolarizations
[7]. Consequently, both hyperglycemia and hypoglycemia
need to be avoided to prevent aggravation of underlying
brain damage.
As shown by van den Berghe and colleagues maintaining
normoglycemia is of imminent importance to significantly
reduce mortality and improve outcome in surgical and med-
ical intensive care unit (ICU) patients [8,9]. However, fol-
lowing severe traumatic brain injury (TBI) keeping low
arterial blood glucose levels between 3.5 and 6.5 mM was
associated with increased intracranial pressure (ICP) and
sustained norepinephrine requirements to maintain cerebral
perfusion pressure (CPP) [10]. Correcting hyperglycemia
(>10 mM) has also been shown to significantly reduce mor-
tality following severe TBI [3] but special care has to be
taken to avoid inducing hypoglycemia [8-15].
To date, the optimal blood glucose range still remains elu-
sive and requirements are discussed controversially as cor-
roborated by the recently published results from the
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Using Glucose Algorithm Regulation (NICE-SUGAR)
trial, which showed a significant increase in mortality in
patients subjected to the tight blood glucose range of 4.5 to
6.0 mmol/l compared with the conventional glucose control
group with a blood glucose target of 10 mmol/l or less [15].
In patients with acute traumatic [16-18] and ischemic
[19,20] brain damage microdialysis is used to gain detailed
insight into otherwise occult metabolic alterations. In this
context, glucose, lactate, pyruvate, and glutamate are rou-
tinely measured [6,16,21,22]. In addition, calculating dif-
ferent indices allows the unmasking of alterations, which
are missed when only considering (normal) absolute values.
In this context, the widely used lactate/pyruvate (L/P) ratio
unmasks impaired mitochondrial function with sustained
cytosolic glycolysis due to diminished or absent oxidative
phosphorylation. This results in reduced pyruvate levels
due to insufficiently replenished nicotinamide adenine
dinucleotide (NAD+) and increased lactate levels due to
metabolic short-cutting as pyruvate is metabolized to lac-
tate by lactate dehydrogenase and cannot enter the citric
acid cycle. Sustained activation of lactate dehydrogenase
insufficiently replenishes NAD+. L/P is increased by isch-
emia-induced anaerobic glycolysis as well as cytokine-
mediated and free radical-mediated mitochondrial damage
observed following severe TBI resulting in non-oxidative
glycolysis [23]. Increased cerebral L/P unmasking meta-
bolic failure has been shown to preceed rises in ICP, under-
scoring its importance within bedside metabolic monitoring
[16].
Increased lactate/glucose (L/Glc) ratio reflects sustained
lactate production driven by hypoxia-induced and isch-
emia-induced hyperglycolysis encountered following TBI
[24-27] and unmasks functional adaptation processes.
Although elevated L/Glc ratio is associated with worse out-
come [27], lactate has also been shown to fuel energy-
requiring processes. In this context, astrocytes produce lac-
tate from glutamate previously released by neurons, which
is then consumed by neurons even during conditions of pre-
served aerobic glycolysis [28,29].
Excessive glutamate-mediated neuronal activation has
been shown to increase lactate production under experi-
mental conditions [30], thus allowing the unmasking of glu-
tamate-driven metabolic impairment by calculating the
lactate/glutamate (L/Glu) ratio.
In an attempt to define optimal blood and brain glucose
concentrations, we retrospectively analyzed the influence of
different arterial blood and brain glucose levels on changes
in cerebral metabolism including the calculated L/P, L/Glc,
and L/Glu ratio determined by microdialysis in 20 patients
with severe TBI requiring prolonged analgesia and seda-
tion. In addition, tissue partial oxygen pressure (ptiO2), jug-
ularvenous oxygen saturation (SjvO2), ICP, CPP,
temperature, as well as administration of insulin and nor-
epinephrine were evaluated.
Materials and methods
A total of 20 patients with severe TBI treated at our ICU
between August 2007 and September 2008 were investi-
gated in the present study. Extended monitoring using cere-
bral microdialysis in conjunction with ICP, ptiO2, and
SjvO2 is an integral part of our routine ICU treatment proto-
col in critically ill patients with severe TBI. The study pro-
tocol was approved by the local ethics committee. Informed
consent for data collection and retrospective evaluation was
obtained from relatives.
Standardized clinical management
Intubated and ventilated patients were treated according to
our standardized interdisciplinary treatment protocol. Fol-
lowing radiologic, diagnostic, and surgical interventions
including insertion of an ICP probe (Neurovent®, Rau-
medic® AG, 95205 Münchberg, Germany) patients were
transferred to our ICU. After 24 hours, a control CT scan
was performed to exclude development of a frontal contu-
sion. Thereafter, a multilumen bolt (Licox® IM3 bolt sys-
tem, Integra Life Sciences Switzerland, 1258 Perly-Geneve,
Switzerland) was inserted in the frontal lobe via a twist drill
burrhole. With this three lumen bolt, a ptiO2 probe (Licox®
IMC oxygen catheter micro probe, Integra Life Sciences
Switzerland, 1258 Perly-Geneve, Switzerland), a brain tem-
perature probe (Licox® IMC temperature micro probe, Inte-
gra Life Sciences Switzerland, 1258 Perly-Geneve,
Switzerland) and a microdialysis catheter (CMA 70
microdialysis bolt catheter, CMA Microdialysis AB 171 18,
Solna, Sweden) were inserted. Based on our standardized
protocol, the three lumen bolt is inserted in the predomi-
nantly injured hemisphere avoiding direct placement in a
frontal contusion. As the probes are not positioned until
after obtaining a control CT scan approximately 24 hours
after TBI, placement within a growing contusion is
avoided.
Continuous analgesia (with fentanyl, Sintenyl® (SINTET-
ICA SA Pharmaceuticals, 6850 Mendrisio, Switzerland))
and sedation (midazolam, Dormicum® (Roche Pharma AG,
4153 Reinach, Switzerland)) was controlled by bispectral
electroencephalography (BIS VISTA, Aspect Medical Sys-
tems, Inc., One Upland Road, Norwood, MA, USA). Drug
dosage was tapered to maintain a BIS level between 20 and
40. Norepinephrine, dobutamine, and volume of critalloids
and colloids were administered to influence CPP. Differen-
tiated CPP management was guided by ptiO2, microdialy-
sis, and transcranial duplex sonography, which allowed
CPP to be tapered to values as low as 60 mmHg, depending
on the actual requirement. Ventilation and partial pressure
of arterial carbon dioxide (paCO2) as well as oxygenation
settings (fraction of inspired oxygen, positive end expira-
tory pressure, and partial pressure of arterial oxygen
(paO2)) were guided by SjvO2 and ptiO2 maintaining SjvO2Meierhans et al. Critical Care 2010, 14:R13
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above 60% and ptiO2 above 15 mmHg. Transfusion of red
blood cells was guided by ptiO2 values keeping hematocrit
at 24% (8 g/dl) or above and ptiO2 at 15 mmHg or above;
i.e., whenever decreased hematocrit below 24% was associ-
ated with signs of cerebral metabolic impairment and insuf-
ficient oxygenation, one unit of red blood cells was
transfused. Brain temperature was maintained between 35.0
and 36.0°C using cooling blankets or an intravenous cool-
ing system (Intravascular Temperature Management:
IVTM™, Alsius® Irvine, CA, USA). Treatment measures
were adapted and tapered to maintain ICP below 15 mmHg.
Only after optimization of all therapeutic interventions did
we accept an ICP of 20 mmHg. Patients received enteral
nutrition via gastric or jejunal tube within the first 12 hours
upon admission to the ICU. Administered calories was
adapted according to indirect calorimetry using the Delta-
trac™ II (Datex-Ohmeda, GE Healthcare Chalfont St Giles,
Bucks UK) performed at least twice weekly. Arterial blood
glucose levels were maintained between 4 and 8 mM by
adapting insulin dose and/or administered amount of nutri-
tion, depending on the clinical situation and the actual
requirements.
Microdialysis and blood glucose analysis
Extracellular brain glucose, lactate, pyruvate, and glutamate
were determined by microdialysis. For this, the intracere-
bral CMA 70 bolt catheter® (10 mm membrane length,
membrane cut-off: 20 kDa, CMA Microdialysis AB 171 18,
Solna, Sweden) was perfused with commercially available
perfusion solutions (Perfusion Fluid CNS, CMA Microdial-
ysis AB 171 18, Solna, Sweden; NaCl 147 mM, KCl 2.7
mM, CaCl2 1.2 mM, MgCl2 0.85 mM) at a fixed rate of 1.0
μl/min using the CMA 107 MD pump® with adjustable flow
rate as reported by Vespa and colleagues [6]. Based on the
lower recovery rate at the used flow rate of 1.0 μl/min
obtained values were multiplied by 3.3 according to the
data published by Hutchinson and colleagues [31,32].
Microdialysis samples were collected over 60 minutes
and then analysed using the bedside CMA 600 Microdialy-
sis Analyzer® (CMA Microdialysis AB 171 18, Solna, Swe-
den), and dialyzed glucose, lactate, pyruvate, and glutamate
levels were determined by enzymatic photometric assay.
Arterial blood glucose was measured by an enzymatic-
amperometric procedure in the routinely performed blood
gas analysis using the ABL825 Flex Analyzer® (Radiome-
ter Medical ApS, Åkadevej 21, DK-2700 Brønshøj, Den-
mark) as previously reported [8,33].
Data evaluation
To avoid confounding influences related to hyperventilation
and ischemia, data points were only included if SjvO2 was
above 55% and ptiO2 was above 10 mmHg [34,35].
Although microdialysis probes were sampled in 60-min-
ute intervals, arterial blood samples were drawn in one to
four-hour intervals, depending on the clinical situation to
correct and adapt ventilator settings (paO2 and paCO2) or to
adapt insulin dose according to the measured arterial blood
glucose levels. For the present analysis, only cerebral
microdialysis samples obtained at the same time point of
arterial blood glucose measurement were evaluated.
Arterial blood glucose levels between 4.0 and 8.0 mM
were considered normoglycemic; blood glucose levels
exceeding 8.0 and below 4.0 mM were defined as hypergly-
cemic and hypoglycemic, respectively.
Search for optimal blood glucose levels was performed
by assessing changes in brain metabolism. For this glucose,
lactate, pyruvate, glutamate, and the calculated L/P, L/Glc,
L/Glu ratios were determined at different pre-defined arte-
rial blood and brain glucose clusters.
Statistical analysis
Changes in cerebral metabolic parameters are shown as box
plots. Significant differences were determined by analysis
of variance (ANOVA) on ranks followed by post hoc multi-
ple comparisons (Dunn's method). Differences were rated
significant at P < 0.05. Graphical and statistical analysis
were performed using SigmaPlot10®  and SigmaStat3.5®
(Systat Software, Inc. San Jose, CA., USA), respectively.
Results
Patient data
A total of 20 patients (9 female and 11 male patients) with
an average age of 29 years (range 16 to 62 years) were
investigated. Although seven patients presented with an
isolated head injury, 13 had additional injuries with a
median abbreviated injury score (AIS) 5 and injury severity
score (ISS) 29. On average, the initial Glasgow coma score
was 7 (3 to 14), 18 patients exhibited mixed cerebral
lesions, length of ICU stay was 27 days (5 to 54 days) and
microdialysis was performed for 14 days (4 to 39 days). Of
these 20 investigated patients, three patients died. Microdi-
alysis catheter and ptiO2/temperature probes were inserted
in the edematous hemisphere with 8 in the right frontal lobe
and 12 in the left frontal lobe. Insertion of probes did not
induce hemorrhagic damage.
Microdialysis data
A total of 3,102 corresponding arterial blood and brain
microdialysis readings were obtained. Distribution of mea-
surements within pre-defined glucose clusters are given in
Table 1. Based on the arterial blood glucose target used in
clinical routine the majority of measurements were within
the blood glucose clusters 5 to 8 mM (Table 1). Time-
dependent changes were considered by investigating the
influence of arterial blood and brain glucose on the differ-
ent parameters of brain metabolism determined by microdi-Meierhans et al. Critical Care 2010, 14:R13
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alysis. As there were no significant differences between
weeks one, two, and three (data not shown), all data points
were summarized.
Influence of arterial blood glucose levels on cerebral 
metabolism
Increasing arterial blood glucose levels grouped in pre-
defined clusters revealed a steady and significant increase
in brain glucose levels at arterial blood glucose levels above
6 mM compared with arterial blood glucose values less than
6 mM (P < 0.001, ANOVA on ranks, post hoc Dunn's test;
Figure 1). The calculated brain-to-blood glucose ratio was
significantly reduced at arterial blood glucose levels above
5 mM (P < 0.001, ANOVA on ranks, post hoc Dunn's test;
Figure 1).
Although cerebral L/P ratio was not influenced by arterial
blood glucose levels, calculated L/Glc ratio was signifi-
cantly decreased at arterial blood glucose levels above 6
mM (P < 0.001, ANOVA on ranks, post hoc Dunn's test;
Figure 2).
Increasing arterial blood glucose levels were associated
with a significant increase in brain glutamate and a signifi-
cant decrease in calculated L/Glu ratio at arterial blood glu-
cose concentrations above 6 mM (P < 0.001, ANOVA on
ranks, post hoc Dunn's test; Figure 3).
Influence of brain glucose levels on cerebral metabolism
Increasing brain glucose concentrations significantly
decreased calculated L/P and L/Glc ratio at brain glucose
levels above 1 mM (P < 0.001, ANOVA on ranks, post hoc
Dunn's test; Figure 4). There was a further significant
decrease at brain glucose concentrations above 3 mM,
reaching lowest values at brain glucose above 6 mM.
Brain glucose levels exceeding 5 mM was associated
with a significant increase in cerebral glutamate concentra-
tions and in parallel with a significant decrease in calcu-
lated L/Glu ratio (P < 0.001, ANOVA on ranks, post hoc
Dunn's test; Figure 5).
Impact of insulin on brain metabolism, glutamate and 
lactate-to-glutamate ratio
Overall, arterial blood glucose levels were significantly
increased whenever insulin was given (7 ± 0.03 vs. 6.1 ±
0.02 mM; P < 0.001). Overall, administration of insulin was
associated with significantly increased extracellular brain
glucose (2.5 ± 0.05 vs. 1.9 ± 0.03; P < 0.001), significantly
decreased brain lactate (4.4 ± 0.02 vs. 5 ± 0.05 mM; P <
0.001), significantly reduced L/Glc ratio (0.46 ± 0.02 vs.
3.7 ± 0.1; P < 0.001), significantly elevated brain glutamate
(17 ± 0.4 vs. 10 ± 0.4 μM; P < 0.001), and significantly
decreased L/Glu ratio (0.47 ± 0.02 vs. 0.9 ± 0.03; P  <
0.001).
Administration of insulin at brain glucose less than 5 mM
(the threshold determined in Figure 5) was associated with
a significant increase in brain glutamate (Figure 6a) and
unchanged brain lactate levels (3.8 to 5.3 mM) resulting in
a significantly decreased L/Glu ratio (Figure 6b). In addi-
tion, L/Glc ratio was significantly reduced at brain glucose
below 5 mM (2.9 ± 0.06 vs 3.7 ± 0.1 mM; P < 0.001) and
brain glucose above 5 mM (0.83 ± 0.03 vs. 0.94 ± 0.06
mM; P  = 0.049) under the influence of insulin. Arterial
blood glucose levels were significantly increased whenever
insulin was administered compared with time points when
insulin was not infused (Figure 6b).
Influence of arterial blood and brain glucose on ptiO2, 
SjvO2, ICP, and CPP
ptiO2, SjvO2, ICP, and CPP were not influenced by the dif-
ferent arterial blood or brain glucose concentrations (Table
1) or the administration of insulin (data not shown).
Table 1: Changes in ICP, CPP, ptiO2, SjvO2, and insulin requirements for different arterial blood glucose clusters
Blood 
glucose
<5 mM 5-5.9 mM 6-6.9 mM 7-7.9 mM 8-8.9 mM >9 mM
n (Σ = 3102) 125 744 1195 736 221 81
4.0% 23.9% 38.5% 23.7% 7.1% 2.6%
ICP (mmHg) 14, 0-50 14, 0-59 14, 1-74 15, 0-92 15, 0-53 15, 1-88
CPP (mmHg) 76, 47-98 78, 51-115 79, 32-111 79, 30-146 78, 60-120 77, 27-109
ptiO2 (mmHg) 31, 15-50 31, 17-81 32, 13-80 31, 11-79 28, 11-77 31, 16-54
SjvO2 (%) 72, 60-93 67, 59-90 71, 59-87 70, 47-93 81, 65-92 79, 57-95
Insulin
(units/h)
0, 0-2.5 0, 0-2.5 0, 0-3.3 0.2, 0-3.3 0.8, 0-3.3 1, 0-2.5
CPP = cerebral perfusion pressure; ICP = intracranial pressure; ptiO2 = tissue oxygen partial pressure; SjvO2 = jugularvenous oxygen 
saturation.
Results are shown as median, range (min to max)Meierhans et al. Critical Care 2010, 14:R13
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Discussion
The present study depicts the impact of blood and brain glu-
cose levels and the effects of insulin on post-traumatic cere-
bral metabolism using bedside microdialysis in a routine
intensive care setting. The calculated metabolic indices L/P,
L/Glc, and L/Glu appear helpful in identifying optimal arte-
rial blood and brain glucose levels. The present results sug-
gest that brain glucose below 1 mM should be avoided and
arterial blood glucose above 5 mM to 9 mM promoted.
Insulin was associated with signs of improved cerebral
metabolism reflected by significantly increased interstitial
glucose, diminished lactate, reduced L/Glc ratio, and
decreased L/Glu ratio.
Cerebral glucose uptake and glucose transporter
Glucose is the predominant cerebral energetic compound,
fueling both neurons and astrocytes [36]. In TBI patients,
glucose was metabolized to both lactate and pyruvate with-
out signs of anaerobic metabolism as reflected by
unchanged L/P ratio [18]. Cerebral glucose uptake occurs
via various glucose transporter (GLUT) proteins located in
microvascular endothelial cells (GLUT1), glia (GLUT1),
and neurons (GLUT3) [37], which are facilitative and
energy-independent transporters mediating glucose equili-
bration. Glucose accumulation is avoided by the bi-direc-
tional flux, which is influenced by the glucose
concentration gradient [37]. The different uptake kinetics
defined by the Michaelis-Menten equation (Km) guarantee
glucose uptake even at low blood glucose levels, which is
essential for neurons especially during hypoglycemia
(GLUT3: 2.8 mM, GLUT1: 8 mM) [37]. Glucose uptake
mediated by GLUT1 and GLUT3 occurs independent of
insulin. Following experimental TBI, significantly
increased GLUT3 and significantly decreased GLUT1 [38]
suggests a mechanism of autoprotection against hypoglyce-
mia due to increased expression of high affinity GLUT3
transporters (Km 2.8 mM). It is unknown if this is also valid
in humans. The present results allow us to speculate about
possible functional alterations of glucose uptake. In this
context, cerebral glucose uptake expressed by the calcu-
lated brain glucose to blood glucose ratio was significantly
increased at low blood glucose below 5 mM followed by a
significant decrease at arterial blood glucose of more than 5
mM, reaching lowest brain-to-blood glucose ratio levels at
blood glucose above 8 mM. This pattern suggests func-
tional adaptive processes possibly by increased GLUT
Figure 1 Changes in brain glucose determined by microdialysis (grey box plots) and calculated brain-to-blood glucose ratio (white box 
plots) in pre-defined blood glucose clusters, ranging from less than 5 mM to more than 9 mM in 1 mM buckets. At arterial blood glucose levels 
exceeding 6 mM brain glucose was significantly increased. With increasing arterial blood glucose and brain glucose levels calculated brain-to-blood 
glucose ratio was significantly decreased, reflecting reduced cerebral uptake. Increases across the pre-defined blood glucose clusters compared with 
low arterial blood glucose levels were significant (*P < 0.001; analysis of variance on ranks, post hoc Dunn's test).
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transporter activity at low arterial blood glucose levels and
decreased GLUT transporter activity at higher arterial
blood glucose levels. This could reflect a saturation effect
as suggested by experimental data showing that the bi-
directional flux is influenced by the glucose concentration
gradient, which reduces GLUT activity at increased brain
glucose levels [37]. An alternative explanation could be a
diffusion gradient effect. However, the missing further
increase in brain glucose at arterial blood glucose of more
than 8 mM with the observed plateau is in favor of a tightly
regulated glucose uptake as suggested under experimental
conditions [37]. Overall, the presently observed profile sug-
gests that arterial blood glucose levels above 8 mM are not
required to supply the brain with sufficient amounts of glu-
cose.
Cerebral glucose metabolism, lactate-to-pyruvate ratio, 
and lactate-to-glucose ratio
Based on experimental and clinical studies glycolysis is not
only regionally and temporally heterogeneous
[18,24,25,28,39] but is also influenced by the functional
posttraumatic changes of various enzymes important in reg-
ulating glucose metabolism such as glucokinase (hexoki-
nase) [40], pyruvate dehydrogenase [41], and the pentose
phosphate pathway [42]. This contributes to impaired sub-
strate utilization and substrate production, resulting in
reduced mitochondrial ATP production. In addition, post-
traumatic mitochondrial damage and disturbed oxidative
phosphorylation force cytosolic glycolysis, which increases
lactate production. Lactate is then metabolized to pyruvate
to generate ATP [18]. This metabolic deviation is reflected
by elevated L/P ratio used to unmask energetic crisis
[6,16,18,22] caused by ischemia (anaerobic glycolysis) and
mitochondrial damage resulting in non-oxidative phospho-
rylation. Although ischemia results in decreased glucose
supply coinciding with reduced ptiO2  and resulting in
decreased cerebral glucose levels, mitochondrial damage is
accepted to deviate glucose degradation via oxidative phos-
phorylation to glycolysis within the cytosolic compartment
even under conditions of sufficient perfusion and sufficient
ptiO2. This, in turn, will exaggerate glucose consumption to
meet aggravated energetic demands because ATP genera-
tion by simple glucose degradation is inferior to complete
metabolism involving the mitochondrial respiratory chain
(aerobic glycolysis). This, in turn, could decrease extracel-
lular glucose levels. Measuring pathologic L/P values at
Figure 2 Changes in calculated brain lactate-to-pyruvate (grey box plots) and lactate-to-glucose (white box plots) ratio determined by mi-
crodialysis reflecting influence of blood glucose on downstream cerebral metabolism in pre- defined arterial blood glucose clusters, rang-
ing from less than 5 mM to more than 9 mM in 1 mM buckets. At arterial blood glucose levels exceeding 6 mM brain lactate-to-glucose ratio was 
significantly decreased. Decreases across the pre-defined blood glucose clusters compared with low arterial blood glucose levels were significant (*P 
< 0.001; analysis of variance on ranks, post hoc Dunn's test).
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ptiO2 levels exceeding the ischemic threshold of 10 mmHg
(median: 30 mmHg, Table 1) [35] suggests that mitochon-
drial dysfunction is the underlying cause for the observed
signs of metabolic impairment reflected by elevated L/P
and L/Glc ratios. Whether this is an adaptive and thus nor-
mal process or if this pattern is to be considered a sign of
irreversible damage cannot be answered by the present
study. Further studies are required to determine if relative
changes in ptiO2 reflecting alterations in microcirculatory
perfusion unmask relative ischemia at ptiO2 values above
the ischemic threshold of 10 mmHg. A decrease in ptiO2
from any starting point would be expected to result in
reduced glucose supply. Furthermore, the present data does
not allow us to differentiate if low brain glucose levels
result from impaired perfusion, possibly being a more sen-
sitive parameter for insufficient perfusion compared with
ptiO2 or if decreased brain glucose stems from excessive
glucose metabolism.
As shown by different authors concomitant decrease in
cerebral glucose below 0.7 mM [22] (determined at 0.3 μl/
min) or below 0.2 mM (determined at 1 μl/min) [6] coincid-
ing with an increase in L/P of more than 40 reflected cere-
bral ischemia [6]. An increase in L/P of more than 25 has
also been shown to predict subsequent intracranial hyper-
tension (>20 mmHg) [16].
The calculated L/Glc ratio is a marker of increased glyco-
lysis resulting either from exaggerated substrate supply, i.e.,
hyperglycemia [2], impaired enzymatic function, or struc-
tural and functional mitochondrial damage with a subse-
quent shift from oxidative/aerobic to non-oxidative and
even to ischemia-induced anaerobic glycolysis [35]. A
combination of elevated blood glucose levels with an addi-
tional insult such as ischemia will aggravate the production
of free oxygen radicals, which mediate further structural
and functional damage [43]. Metabolic and energetic
impairment resulting in increased lactate and tissue acidosis
[1,44] will induce glial and neuronal cell swelling [45]. An
increased L/Glc ratio has also been demonstrated to be a
predictor of adverse outcome in TBI patients [27,46].
The observed decrease in L/Glc ratio with increased
blood and brain glucose concentrations could result from
reduced oxygen and ATP consumption due to sufficient
Figure 3 Changes in brain glutamate (grey box plots) and calculated lactate-to-glutamate (white box plots) ratio determined by microdi-
alysis reflecting influence of blood glucose on downstream cerebral metabolism in pre-defined arterial blood glucose clusters, ranging 
from less than 5 mM to more than 9 mM in 1 mM buckets. At arterial blood glucose levels exceeding 6 mM brain glutamate was significantly in-
creased. In parallel, calculated lactate-to-glutamate was significantly decreased. Alterations across the pre-defined blood glucose clusters compared 
with low arterial blood glucose levels were significant (*P < 0.001; analysis of variance on ranks, post hoc Dunn's test).
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glucose supply, which attenuates lactate production as an
alternative energetic compound.
The present study clearly shows that signs of downstream
metabolic impairment are influenced differently by blood
and brain glucose concentrations. Although L/P ratio is not
influenced by low blood glucose below 5 mM, L/Glc was
significantly increased. Within the cerebral compartment,
low brain glucose below 5 mM was associated with a sig-
nificant increase in L/P and L/Glc. Highest L/P and L/Glc
values were observed at brain glucose below 1 mM with a
steady decrease at increasing brain glucose levels. This
clearly shows that blood glucose levels do not reflect cere-
bral glucose metabolism. The observed stable L/P and L/
Glc values at brain glucose above 6 mM suggest that higher
brain glucose concentrations are required than currently
accepted.
Cerebral glutamate and lactate-to-glutamate ratio
Glutamate, known for its excitotoxic potential, is main-
tained at low levels due to highly efficient glial and neu-
ronal uptake [47]. Under pathologic conditions, insufficient
oxygen and glucose supply resulting in energetic perturba-
tion impairs ATP-dependent pump processes. Conse-
quently, extracellular glutamate increases due to excessive
neuronal activation, reversal of glutamate uptake, and leak-
age from damaged astrocytes and neurons [48]. According
to the present study, interstitial glutamate was significantly
increased at low brain glucose below 2 mM (Figure 5), sug-
gesting sustained release due to depolarization-induced glu-
tamate efflux caused by low glucose levels [49].
Pathogenity of elevated glutamate is reflected by the signif-
icant increase in cerebral L/Glu ratio. This is in line with
experimental and clinical studies showing that glutamate
induces glycolysis and lactate production [30,50]. The pres-
ently observed increase in glutamate corresponds, at least in
part, to the results published by Vespa and colleagues inves-
tigating the impact of low arterial blood glucose between
4.4 and 6.1 mM [6]. In the present post hoc analysis,
increasing brain glucose by more than 4 to 5 mM was asso-
ciated with significantly elevated brain glutamate. How-
Figure 4 Changes in calculated brain lactate-to-pyruvate (grey box plots) and lactate-to-glucose (white box plots) ratio determined by mi-
crodialysis reflecting influence of brain glucose on downstream cerebral metabolism in pre-defined brain glucose clusters, ranging from 
less than 1 mM to more than 9 mM in 1 mM buckets. At brain glucose levels exceeding 1 mM brain lactate-to-pyruvate and lactate-to-glucose 
were significantly decreased. Changes across the pre-defined brain glucose clusters compared with low brain glucose levels (<1 mM) were significant 
(*P < 0.001; analysis of variance on ranks, post hoc Dunn's test).
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ever, contrary to elevated brain glutamate at low brain
glucose values the significantly increased brain glutamate
concentrations at higher brain glucose were associated with
an significant decrease in L/Glu. This suggests a different
pathologic impact of glutamate depending on the underly-
ing brain glucose level and the degree of energetic impair-
ment. Although low brain glucose promotes energetic
failure with subsequent glutamate release and glutamate-
mediated lactate production (increased L/Glu), high brain
glucose levels seem to support production of energy-related
compounds such as glutamate, which is an essential key
player within the intermediate metabolism. Based on in
vivo as well as in vitro studies, metabolized glucose is used
to synthesize various amino acids, such as glutamate, glu-
tamine, and alanine in addition to fueling energy-producing
pathways [51,52]. Glutamate also facilitates entry of other
amino acids to the citric acid cycle with subsequent oxida-
tive phosphorylation for subsequent ATP generation,
thereby attenuating signs of energetic distress as reflected
by decreased L/Glu ratio in the present study.
Elevated brain glutamate can also result from insulin-
mediated reduced glucose availability resulting in reversal
of glutamate uptake processes [53]. In vitro insulin impairs
glial glutamate uptake by reducing expression of GLAST/
EAAT1 transporter [54] and by possibly impairing ATP-
dependent pump processes resulting in transmitter exocyto-
sis [55]. These alterations could explain insulin-mediated
increases in brain glutamate at low brain glucose levels
below 5 mM compared with episodes in which insulin was
not administered. At brain glucose levels above 5 mM,
administered insulin did not influence brain glutamate, sug-
gesting that underlying brain glucose level is important to
prevent insulin-induced increase in interstitial glutamate.
Contrary to the suggested pathologic influence of insulin
on elevated glutamate levels at low brain glucose values,
analysis of downstream metabolism revealed significantly
decreased L/Glu values (Figure 6). This, in turn, attributes a
positive effect to insulin administration even at low brain
glucose of 5 mM or less despite significantly increased
brain glutamate concentrations. At brain glucose values
Figure 5 Changes in brain glutamate (grey box plots) and calculated brain lactate-to-glutamate (white box plots) ratio determined by mi-
crodialysis reflecting influence of brain glucose on downstream cerebral metabolism in pre-defined brain glucose clusters, ranging from 
less than 1 mM to more than 9 mM in 1 mM buckets. At brain glucose levels exceeding 5 mM brain glutamate was significantly increased. In parallel 
lactate-to-glutamate was significantly decreased. Changes across the pre-defined brain glucose clusters compared with low brain glucose levels were 
significant (*P < 0.001; analysis of variance on ranks, post hoc Dunn's test).
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above 5 mM, L/Glu was not influenced by insulin adminis-
tration.
Further in-depth analysis in a prospective setting with
pre-defined criteria in terms of glucose level and insulin
dose are required to interpret the present findings and to
define safe brain-glucose dependent insulin dose.
Influence of insulin on cerebral metabolism
As suggested by the present data, glucose uptake could be
insulin-dependent because insulin administration was asso-
ciated with significantly increased interstitial brain glucose.
This is in line with the findings of insulin-mediated
increases in mean global rate of brain glucose utilization
determined in healthy volunteers by 18-fluorodeoxyglucose
positron emission tomography [56]. This, in turn, could
also explain the signs of improved brain metabolism
reflected by significantly decreased brain lactate, signifi-
cantly reduced L/Glc ratio, and significantly decreased L/
Glu ratio. However, the present data does not allow us to
determine whether glucose uptake occured via insulin-sen-
sitive (GLUT 4) and partially insulin sensitive (GLUT 1)
glucose transporters [37] or was merely caused by the sig-
nificantly increased arterial blood glucose levels, or a com-
bination of both.
Limitations of the present study
Changes in brain glucose were compared with alterations in
arterial blood glucose. For this, two different techniques
with different time intervals and analytical procedures were
used. To compare brain and blood glucose values, microdi-
alysis samples were only considered at matching time
points of arterial blood glucose analysis. This, in turn, only
allows a discontinuous snap-shot view of changes in blood
and brain, and precludes the assessment of influences of
glucose and insulin in real time. Nevertheless, the chosen
approach reveals significant and clinically relevant
changes. Further in-depth analysis of continuously mea-
sured blood glucose levels via intravenous microdialysis
determined in parallel to cerebral microdialysis is required
for real-time assessment. Prospective analysis is required to
assess the influence of insulin at pre-defined blood and
brain glucose levels with the aim of identifying potentially
deleterious episodes possibly related to relative and even
individual thresholds of hypoglycemia.
The pre-defined arterial blood glucose target ranging
from 5 to 8 mM not only determines the frequency of blood
glucose values (5 to 8 mM in 86%, < 5 mM in 4%, > 8 mM
9.7%) but also influences interpretation of the obtained data
as insulin and nutrition were adapted according to measured
arterial blood glucose.
Conclusions
The present results underscore the necessity of integrating
microdialysis and calculated indices of downstream metab-
olism such as L/P, L/Glc, and L/Glu for bedside evaluation
of otherwise occult changes in cerebral metabolism. This is
Figure 6 Changes in (a) brain glutamate, (b) calculated brain lactate-to-glutamate ratio, and arterial blood glucose determined by cerebral 
microdialysis investigating the influence of time points with insulin (grey box plots) and without insulin (white box plots) administration 
in pre-defined brain glucose clusters. At brain glucose levels ≤ 5 mM brain glutamate was significantly increased under the influence of insulin 
compared with time points without insulin administration (*P < 0.001, Mann-Whitney test). In parallel lactate-to-glutamate was significantly decreased 
(*P < 0.001, Mann-Whitney test). At brain glucose levels >5 mM insulin did not influence brain glutamate or lactate-to-glutamate ratio. Whenever in-
sulin was administered, arterial blood glucose was significantly increased compared with time points insulin was not given (*P < 0.001, Mann-Whitney 
test).
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important when defining optimal blood and brain glucose
levels with the aim of avoiding deleterious consequences of
routine therapeutic interventions such as insulin administra-
tion. Optimal cerebral glucose supply appears to be present
at arterial blood and brain glucose levels between 6 and 8
mM. Absent pathogenity of elevated brain glutamate levels
observed at brain glucose levels above 5 mM is unveiled by
significantly decreased L/Glu ratio. Despite an increase in
brain glutamate at brain glucose below 5 mM insulin
appears to be neuroprotective reflected by the significantly
decreased L/Glu and signs of improved cerebral metabo-
lism. Prospective investigations integrating pre-defined
changes in glucose and insulin administration (considering
dose, duration, and metabolic changes) are required to care-
fully differentiate protective from possibly deleterious con-
sequences of insulin administration.
Key messages
• Cerebral microdialysis is important for detailed insight
into cerebral metabolic alterations, which are missed by
simply investigating the impact of insulin on changes in
arterial blood glucose levels.
• Assessing changes in cerebral glutamate and calculating
metabolic indices, i.e., L/P, L/Glc, and L/Glu, are useful in
unmasking signs of downstream metabolism, which remain
undiscovered when only measuring brain glucose.
• Blood glucose concentrations below 6 mM and brain
glucose levels below 1 mM should be avoided.
• Pathogenity of increased brain glutamate concentrations
at brain glucose levels below 3 mM and above 5 mM is
unmasked by calculated L/Glu ratio revealing pathologic
glutamate values at brain glucose levels below 3 mM.
• Insulin-induced increase in brain glutamate at brain glu-
cose levels below 5 mM is associated with significantly
decreased L/Glu, thus reflecting neuroprotective potential
of infused insulin even at low brain glucose levels.
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